Paclitaxel-coated versus uncoated balloon angioplasty for femoropopliteal artery in-stent restenosis

International Journal of Surgery

Volumn 42, Issue , 2017, Pages 72-82

  Wu, Ridong ^a   Li, Zilun ^a   Wang, Mian ^a   Chang, Guangqi ^a   Yao, Chen ^a   Wang, Shenming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Drug coated balloon; Femoropopliteal artery; In stent restenosis

Indexed keywords

PACLITAXEL;

ANKLE BRACHIAL INDEX; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY RISK; DEVICE SAFETY; DIABETES MELLITUS; FEMOROPOPLITEAL IN STENT RESTENOSIS; HUMAN; IN-STENT RESTENOSIS; META ANALYSIS; OUTCOME ASSESSMENT; PACLITAXEL COATED BALLOON ANGIOPLASTY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ADVERSE DEVICE EFFECT; COMPARATIVE STUDY; FEMORAL ARTERY; PATHOLOGY; POPLITEAL ARTERY; PROCEDURES; PROSPECTIVE STUDY; STENOSIS, OCCLUSION AND OBSTRUCTION; STENT;

ANGIOPLASTY, BALLOON; CONSTRICTION, PATHOLOGIC; FEMORAL ARTERY; HUMANS; PACLITAXEL; POPLITEAL ARTERY; PROSPECTIVE STUDIES; STENTS;

EID: 85019005111     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2017.04.057     Document Type: Review

References (25)

1. [1] Van Den Berg, J.C., Management of in-stent restenosis in the superficial femoral artery. J. Cardiovasc. Surg. 57:2 (2016), 248–256.
2. [2] Teleb, M., Wardi, M., Gosavi, S., Said, S., Mukherjee, D., Paclitaxel-coated balloons: review of a promising interventional approach to preventing restenosis in femoropopliteal arteries. Int. J. Angiol. Off. Publ. Int. Coll. Angiol. 25:2 (2016), 75–80.
3. [3] Donas, K.P., Torsello, G., Schwindt, A., Schönefeld, E., Boldt, O., Pitoulias, G.A., Below knee bare nitinol stent placement in high-risk patients with critical limb ischemia is still durable after 24 months of follow-up. J. Vasc. Surg. 52:2 (2010), 356–361.
4. [4] Lin, P.H., Weakley, S.M., Kougias, P., How to interpret data from the superficial femoral artery stenting trials and registries. Semin. Vasc. Surg. 23:3 (2010), 138–147.
5. [5] Bosiers, M., Deloose, K., Callaert, J., Verbist, J., Hendriks, J., Lauwers, P., Schroe, H., Lansink, W., Scheinert, D., Schmidt, A., Zeller, T., Beschorner, U., Noory, E., Torsello, G., Austermann, M., Peeters, P., Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial. J. Endovascular Ther. 22:1 (2015), 1–10.
6. [6] Sobieszczyk, P., In-stent restenosis after femoropopliteal interventions with drug-eluting stents: same but different?. JACC. Cardiovasc. Interv. 9:8 (2016), 835–837.
7. [7] Iida, O., Takahara, M., Soga, Y., Hirano, K., Yamauchi, Y., Zen, K., Kawasaki, D., Nanto, S., Yokoi, H., Uematsu, M., ZEPHYR Investigators. The characteristics of in-stent restenosis after drug-eluting stent implantation in femoropopliteal lesions and 1-year prognosis after repeat endovascular therapy for these lesions. JACC. Cardiovasc. Interv. 9:8 (2016), 828–834.
8. [8] Singh, G.D., Armstrong, E.J., Laird, J.R., Femoropopliteal in-stent restenosis: current treatment strategies. J. Cardiovasc. Surg. 55:3 (2014), 325–333.
9. [9] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62:10 (2009), 1006–1012.
10. [10] Higgins, J., Green, S., Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. 2009, The Cochrane Collaboration Available at: www.cochrane-handbook.org.
11. [11] Rutherford, R.B., Baker, J.D., Ernst, C., Johnston, K.W., Porter, J.M., Ahn, S., Jones, D.N., Recommended standards for reports dealing with lower extremity ischemia: revised version. J. Vasc. Surg. 26:3 (1997), 517–538.
12. [12] Krankenberg, H., Tübler, T., Ingwersen, M., Schlüter, M., Scheinert, D., Blessing, E., Sixt, S., Kieback, A., Beschorner, U., Zeller, T., Drug-coated balloon versus standard balloon for superficial femoral artery in-stent restenosis: the randomized femoral artery in-stent restenosis (FAIR) trial. Circulation 132:23 (2015), 2230–2236.
13. [13] Kinstner, C.M., Lammer, J., Willfort-Ehringer, A., Matzek, W., Gschwandtner, M., Javor, D., Funovics, M., Schoder, M., Koppensteiner, R., Loewe, C., Ristl, R., Wolf, F., Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial. JACC. Cardiovasc. Interv. 9:13 (2016), 1386–1392.
14. [14] Liistro, F., Angioli, P., Porto, I., Ricci, L., Ducci, K., Grotti, S., Falsini, G., Ventoruzzo, G., Turini, F., Bellandi, G., Bolognese, L., Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. J. Endovascular Ther. Off. J. Int. Soc. Endovascular Special. 21:1 (2014), 1–8.
15. [15] Dippel, E.J., Makam, P., Kovach, R., George, J.C., Patlola, R., Metzger, D.C., Mena-Hurtado, C., Beasley, R., Soukas, P., Colon-Hernandez, P.J., Stark, M.A., Walker, C., EXCITE ISR Investigators. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC. Cardiovasc. Interv. 8:1 Pt A (2015), 92–101.
16. [16] Cannavale, A., Tsetis, D., Krokidis, M., The endovascular approach for in-stent restenosis in femoropopliteal disease. Expert Rev. Cardiovasc. Ther. 13:4 (2015), 391–401.
17. [17] Razzouk, L., Aggarwal, S., Gorgani, F., Babaev, A., In-stent restenosis in the superficial femoral artery. Ann. Vasc. Surg. 27:4 (2013), 510–524.
18. [18] Laird, J.R., Yeo, K.K., The treatment of femoropopliteal in-stent restenosis: back to the future. J. Am. Coll. Cardiol. 59:1 (2012), 24–25.
19. [19] Stabile, E., Virga, V., Salemme, L., Cioppa, A., Ambrosini, V., Sorropago, G., Tesorio, T., Cota, L., Popusoi, G., Pucciarelli, A., Biamino, G., Rubino, P., Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J. Am. Coll. Cardiol. 60:18 (2012), 1739–1742.
20. [20] Gorgani, F., Telis, A., Narakathu, N., LaBarbera, M., Babaev, A., Long-term outcomes of the Viabahn stent in the treatment of in-stent restenosis in the superficial femoral artery. J. Invasive Cardiol. 25:12 (2013), 670–674.
21. [21] Elens, M., Verbist, J., Keirse, K., Van Den Eynde, W., Peeters, P., Which is currently the best strategy for treatment of SFA in-stent restenosis?. J. Cardiovasc. Surg. 55:4 (2014), 477–481.
22. [22] Armstrong, E.J., Thiruvoipati, T., Tanganyika, K., Singh, G.D., Laird, J.R., Laser atherectomy for treatment of femoropopliteal in-stent restenosis. J. Endovascular Ther. Off. J. Int. Soc. Endovascular Special. 22:4 (2015), 506–513.
23. [23] Laird, J.R., Singh, G.D., Drug-coated balloons as the new standard of care for femoropopliteal in-stent restenosis: FAIR assumption?. Circulation 132:23 (2015), 2198–2200.
24. [24] Gray, B.H., Buchan, J.A., The treatment of superficial femoral artery in-stent restenosis: the jury is still out. JACC. Cardiovasc. Interv. 9:13 (2016), 1393–1396.
25. [25] Zeller, T., Rastan, A., Macharzina, R., Beschorner, U., Noory, E., Drug-coated balloons: how should we incorporate into our practice in treating superficial femoral artery lesions?. Curr. Treat. Options Cardiovasc. Med., 17(5), 2015, 380.